EUR 8.7
(0.0%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - EUR | 0.0% |
2022 | - EUR | 0.0% |
2021 | - EUR | -100.0% |
2020 | 42.3 Million EUR | -24.06% |
2019 | 55.7 Million EUR | 1.09% |
2018 | 55.1 Million EUR | -4.34% |
2017 | 57.6 Million EUR | -8.43% |
2016 | 62.9 Million EUR | 127.9% |
2015 | 27.6 Million EUR | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | - EUR | 0.0% |
2024 Q1 | - EUR | 0.0% |
2023 Q1 | - EUR | 0.0% |
2023 FY | - EUR | 0.0% |
2023 Q3 | - EUR | 0.0% |
2023 Q4 | - EUR | 0.0% |
2023 Q2 | - EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 Q2 | - EUR | 0.0% |
2022 FY | - EUR | 0.0% |
2022 Q1 | - EUR | 0.0% |
2022 Q3 | - EUR | 0.0% |
2021 Q4 | - EUR | 0.0% |
2021 FY | - EUR | -100.0% |
2021 Q3 | - EUR | 0.0% |
2021 Q2 | - EUR | 0.0% |
2021 Q1 | - EUR | -100.0% |
2020 Q2 | 53.9 Million EUR | -1.46% |
2020 Q4 | 42.3 Million EUR | 0.0% |
2020 FY | 42.3 Million EUR | -24.06% |
2020 Q3 | 42.3 Million EUR | -21.52% |
2020 Q1 | 54.69 Million EUR | -1.8% |
2019 Q4 | 55.7 Million EUR | 0.0% |
2019 FY | 55.7 Million EUR | 1.09% |
2019 Q3 | 55.7 Million EUR | -0.36% |
2019 Q2 | 55.9 Million EUR | 0.0% |
2019 Q1 | 55.9 Million EUR | 1.45% |
2018 Q2 | 54.3 Million EUR | 0.0% |
2018 Q4 | 55.1 Million EUR | 0.0% |
2018 FY | 55.1 Million EUR | -4.34% |
2018 Q1 | 54.3 Million EUR | -5.73% |
2018 Q3 | 55.1 Million EUR | 1.47% |
2017 Q2 | 60.9 Million EUR | 0.0% |
2017 FY | 57.6 Million EUR | -8.43% |
2017 Q3 | 57.6 Million EUR | -5.42% |
2017 Q4 | 57.6 Million EUR | 0.0% |
2017 Q1 | 60.9 Million EUR | -3.18% |
2016 Q3 | 62.9 Million EUR | 149.6% |
2016 Q2 | 25.2 Million EUR | 0.0% |
2016 FY | 62.9 Million EUR | 127.9% |
2016 Q1 | 25.2 Million EUR | -8.7% |
2016 Q4 | 62.9 Million EUR | 0.0% |
2015 Q2 | 32.7 Million EUR | 0.0% |
2015 FY | 27.6 Million EUR | 0.0% |
2015 Q4 | 27.6 Million EUR | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
AB Science S.A. | 16.98 Million EUR | 100.0% |
Boiron SA | 6.64 Million EUR | 100.0% |
Fagron NV | 325.03 Million EUR | 100.0% |
Ipsen S.A. | 341.4 Million EUR | 100.0% |
Vetoquinol SA | 9.66 Million EUR | 100.0% |